Merck and Ridgeback’s COVID-19 oral antiviral molnupiravir joins the pandemic response with U.K. nodnews2021-11-04T14:58:19+00:00November 4th, 2021|Fierce Pharma|
Novartis exits 20-year Roche stake, creating a $20.7B question about CEO Vas Narasimhan’s next M&A movenews2021-11-04T14:34:47+00:00November 4th, 2021|Fierce Pharma|
Shipping delays, supply chain expansions ding Moderna’s COVID-19 vaccine businessnews2021-11-04T13:42:36+00:00November 4th, 2021|Fierce Pharma|
Catalent telegraphs more growth in Indiana with $1.2M land deal: reportnews2021-11-04T13:19:17+00:00November 4th, 2021|Fierce Pharma|
Inceptor Bio snaps up Arranta Bio manufacturing site as it preps to move preclinical cell therapies forwardnews2021-11-04T12:11:16+00:00November 4th, 2021|Fierce Pharma|
For pharma marketers, mobile devices reign supreme. But for how long?news2021-11-04T10:58:46+00:00November 4th, 2021|Fierce Pharma|
ASH: Chasing AbbVie and J&J’s Imbruvica, BeiGene’s Brukinsa fleshes out competitive leukemia data againnews2021-11-04T10:31:41+00:00November 4th, 2021|Fierce Pharma|
Yet another Acceleron investor challenges Merck’s $11.5B acquisition offer: Bloombergnews2021-11-03T15:51:24+00:00November 3rd, 2021|Fierce Pharma|
After a phase of slower growth, Novo Nordisk sees the fruits of its Wegovy and Rybelsus launches, CEO saysnews2021-11-03T15:30:42+00:00November 3rd, 2021|Fierce Pharma|
Incyte investigates all batches of new eczema cream Opzelura after reports of ‘texture problem’news2021-11-03T14:53:04+00:00November 3rd, 2021|Fierce Pharma|
